Dearborn Partners LLC Has $31.67 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Dearborn Partners LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 411,592 shares of the biopharmaceutical company’s stock after buying an additional 58,904 shares during the quarter. Gilead Sciences makes up approximately 1.7% of Dearborn Partners LLC’s investment portfolio, making the stock its 22nd largest position. Dearborn Partners LLC’s holdings in Gilead Sciences were worth $31,668,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in GILD. Capital International Investors increased its position in Gilead Sciences by 336.8% during the first quarter. Capital International Investors now owns 56,369,657 shares of the biopharmaceutical company’s stock worth $4,214,200,000 after buying an additional 43,464,551 shares during the last quarter. Capital World Investors increased its position in Gilead Sciences by 123.0% during the first quarter. Capital World Investors now owns 46,331,318 shares of the biopharmaceutical company’s stock worth $3,463,732,000 after buying an additional 25,555,467 shares during the last quarter. Capital Research Global Investors increased its position in Gilead Sciences by 12.7% during the first quarter. Capital Research Global Investors now owns 95,982,319 shares of the biopharmaceutical company’s stock worth $7,175,643,000 after buying an additional 10,849,434 shares during the last quarter. APG Asset Management N.V. increased its position in Gilead Sciences by 237.9% during the first quarter. APG Asset Management N.V. now owns 2,417,175 shares of the biopharmaceutical company’s stock worth $139,948,000 after buying an additional 1,701,818 shares during the last quarter. Finally, First Trust Advisors LP increased its position in Gilead Sciences by 110.8% during the second quarter. First Trust Advisors LP now owns 3,237,076 shares of the biopharmaceutical company’s stock worth $249,061,000 after buying an additional 1,701,510 shares during the last quarter. 78.74% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CAO Diane E. Wilfong sold 12,264 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $80.09, for a total value of $982,223.76. Following the completion of the transaction, the chief accounting officer now directly owns 23,685 shares in the company, valued at approximately $1,896,931.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Brett A. Pletcher sold 13,210 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total value of $1,046,628.30. Following the completion of the transaction, the executive vice president now owns 27,204 shares of the company’s stock, valued at $2,155,372.92. The disclosure for this sale can be found here. Insiders have sold 28,079 shares of company stock valued at $2,240,630 over the last 90 days. Corporate insiders own 0.13% of the company’s stock.

A number of brokerages have weighed in on GILD. SunTrust Banks boosted their price target on Gilead Sciences from $73.00 to $74.00 and gave the stock a “hold” rating in a research report on Friday. Oppenheimer reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Monday, May 18th. Credit Suisse Group decreased their target price on Gilead Sciences from $75.00 to $73.00 and set a “neutral” rating on the stock in a research report on Friday. UBS Group downgraded Gilead Sciences from a “buy” rating to a “neutral” rating and upped their target price for the company from $77.00 to $80.00 in a research report on Monday, April 27th. Finally, Cfra upped their target price on Gilead Sciences from $71.00 to $74.00 and gave the company a “sell” rating in a research report on Wednesday, April 29th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and nine have issued a buy rating to the stock. Gilead Sciences currently has an average rating of “Hold” and a consensus target price of $79.63.

NASDAQ GILD traded down $2.80 on Friday, hitting $69.53. 20,558,846 shares of the company’s stock were exchanged, compared to its average volume of 6,482,609. The stock has a 50-day moving average of $75.47 and a 200-day moving average of $73.57. The company has a current ratio of 3.04, a quick ratio of 2.92 and a debt-to-equity ratio of 1.00. Gilead Sciences, Inc. has a 52 week low of $60.89 and a 52 week high of $85.97. The stock has a market cap of $90.73 billion, a price-to-earnings ratio of -289.70, a P/E/G ratio of 2.43 and a beta of 0.70.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.46). Gilead Sciences had a positive return on equity of 32.17% and a negative net margin of 1.16%. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.24 billion. As a group, analysts predict that Gilead Sciences, Inc. will post 6.61 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a yield of 3.91%. Gilead Sciences’s payout ratio is presently 44.30%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: Technical Analysis of Stocks, How Can It Help

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.